Literature DB >> 19734292

Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics.

Ignazio Cali1, Rudolph Castellani, Amer Alshekhlee, Yvonne Cohen, Janis Blevins, Jue Yuan, Jan P M Langeveld, Piero Parchi, Jiri G Safar, Wen-Quan Zou, Pierluigi Gambetti.   

Abstract

Five phenotypically distinct subtypes have been identified in sporadic Creutzfeldt-Jakob disease (sCJD), based on the methionine/valine polymorphic genotype of codon 129 of the prion protein (PrP) gene and the presence of either one of the two protease K-resistant scrapie prion protein (PrP(Sc)) types identified as 1 and 2. The infrequent co-existence of both PrP(Sc) types in the same case has been known for a long time. Recently, it has been reported, using type-specific antibodies, that the PrP(Sc) type 1 is present in all cases of sCJD carrying PrP(Sc) type 2. The consistent co-occurrence of both PrP(Sc) types complicates the diagnosis and the current classification of sCJD, and has implications for the pathogenesis of naturally occurring prion diseases. In the present study, we investigated the prevalence of PrP(Sc) types 1 and 2 co-occurrence, along with its effects on the disease phenotype and PrP(Sc) strain characteristics, comparatively analysing 34 cases of sCJD, all methionine homozygous at codon 129 of the PrP gene (sCJDMM). To minimize overestimating the prevalence of the sCJDMM cases carrying PrP(Sc) types 1 and 2 (sCJDMM1-2), we used proteinase K concentrations designed to hydrolyse all fragments resulting from an incomplete digestion, while preserving the protease-resistant PrP(Sc) core. Furthermore, we used several antibodies to maximize the detection of both PrP(Sc) types. Our data show that sCJDMM cases associated exclusively with either PrP(Sc) type 1 (sCJDMM1) or PrP(Sc) type 2 (sCJDMM2) do exist; we estimate that they account for approximately 56% and 5% of all the sCJDMM cases, respectively; while in 39% of the cases, both PrP(Sc) types 1 and 2 are present together (sCJDMM1-2) either mixed in the same anatomical region or separate in different regions. Clinically, sCJDMM1-2 had an average disease duration intermediate between the other two sCJDMM subtypes. The histopathology was also intermediate, except for the cerebellum where it resembled that of sCJDMM1. These features, along with the PrP immunostaining pattern, offer a diagnostic clue. We also observed a correlation between the disease duration and the prevalence of PrP(Sc) type 2 and sCJDMM2 phenotypes. The use of different antibodies and of the conformational stability immunoassay indicated that the co-existence of types 1 and 2 in the same anatomical region may confer special conformational characteristics to PrP(Sc) types 1 and 2. All of these findings indicate that sCJDMM1-2 should be considered as a separate entity at this time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734292      PMCID: PMC2766234          DOI: 10.1093/brain/awp196

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

1.  Antibody to DNA detects scrapie but not normal prion protein.

Authors:  Wen-Quan Zou; Jian Zheng; Donald M Gray; Pierluigi Gambetti; Shu G Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

2.  Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP(Sc) in the same brain.

Authors:  G Puoti; G Giaccone; G Rossi; B Canciani; O Bugiani; F Tagliavini
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

3.  Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy.

Authors:  J C Bartz; R A Bessen; D McKenzie; R F Marsh; J M Aiken
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Genetic influence on the structural variations of the abnormal prion protein.

Authors:  P Parchi; W Zou; W Wang; P Brown; S Capellari; B Ghetti; N Kopp; W J Schulz-Schaeffer; H A Kretzschmar; M W Head; J W Ironside; P Gambetti; S G Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

5.  Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes.

Authors:  Gábor G Kovács; Mark W Head; Ivan Hegyi; Tristan J Bunn; Helga Flicker; Johannes A Hainfellner; Linda McCardle; Lajos László; Christa Jarius; James W Ironside; Herbert Budka
Journal:  Brain Pathol       Date:  2002-01       Impact factor: 6.508

6.  Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease.

Authors:  Wen-Quan Zou; Sabina Capellari; Piero Parchi; Man-Sun Sy; Pierluigi Gambetti; Shu G Chen
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

7.  Effects of different experimental conditions on the PrPSc core generated by protease digestion: implications for strain typing and molecular classification of CJD.

Authors:  Silvio Notari; Sabina Capellari; Armin Giese; Ingo Westner; Agostino Baruzzi; Bernardino Ghetti; Pierluigi Gambetti; Hans A Kretzschmar; Piero Parchi
Journal:  J Biol Chem       Date:  2004-01-29       Impact factor: 5.157

8.  A change in the conformation of prions accompanies the emergence of a new prion strain.

Authors:  David Peretz; R Anthony Williamson; Giuseppe Legname; Yoichi Matsunaga; Julie Vergara; Dennis R Burton; Stephen J DeArmond; Stanley B Prusiner; Michael R Scott
Journal:  Neuron       Date:  2002-06-13       Impact factor: 17.173

Review 9.  Sporadic and familial CJD: classification and characterisation.

Authors:  Pierluigi Gambetti; Qingzhong Kong; Wenquan Zou; Piero Parchi; Shu G Chen
Journal:  Br Med Bull       Date:  2003       Impact factor: 4.291

10.  Effects of human PrPSc type and PRNP genotype in an in-vitro conversion assay.

Authors:  Michael Jones; Alexander H Peden; Darren Wight; Christopher Prowse; Ian Macgregor; Jean Manson; Marc Turner; James W Ironside; Mark W Head
Journal:  Neuroreport       Date:  2008-12-03       Impact factor: 1.837

View more
  70 in total

1.  Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease.

Authors:  Piero Parchi; Maura Cescatti; Silvio Notari; Walter J Schulz-Schaeffer; Sabina Capellari; Armin Giese; Wen-Quan Zou; Hans Kretzschmar; Bernardino Ghetti; Paul Brown
Journal:  Brain       Date:  2010-09-07       Impact factor: 13.501

2.  Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease.

Authors:  Numthip Chitravas; Richard S Jung; Diane M Kofskey; Janis E Blevins; Pierluigi Gambetti; R John Leigh; Mark L Cohen
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

Review 3.  Tracking protein aggregate interactions.

Authors:  Christina J Sigurdson; Jason C Bartz; K Peter R Nilsson
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

Review 4.  The activities of amyloids from a structural perspective.

Authors:  Roland Riek; David S Eisenberg
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 5.  Molecular biology and pathology of prion strains in sporadic human prion diseases.

Authors:  Pierluigi Gambetti; Ignazio Cali; Silvio Notari; Qingzhong Kong; Wen-Quan Zou; Witold K Surewicz
Journal:  Acta Neuropathol       Date:  2010-11-07       Impact factor: 17.088

6.  Diagnostic and prognostic value of human prion detection in cerebrospinal fluid.

Authors:  Aaron Foutz; Brian S Appleby; Clive Hamlin; Xiaoqin Liu; Sheng Yang; Yvonne Cohen; Wei Chen; Janis Blevins; Cameron Fausett; Han Wang; Pierluigi Gambetti; Shulin Zhang; Andrew Hughson; Curtis Tatsuoka; Lawrence B Schonberger; Mark L Cohen; Byron Caughey; Jiri G Safar
Journal:  Ann Neurol       Date:  2017-01       Impact factor: 10.422

7.  Co-occurrence of types 1 and 2 PrP(res) in sporadic Creutzfeldt-Jakob disease MM1.

Authors:  Atsushi Kobayashi; Kenta Mizukoshi; Yasushi Iwasaki; Hajime Miyata; Yasuji Yoshida; Tetsuyuki Kitamoto
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

8.  The octarepeat region of the prion protein is conformationally altered in PrP(Sc).

Authors:  Alice Y Yam; Carol Man Gao; Xuemei Wang; Ping Wu; David Peretz
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  A new method for the characterization of strain-specific conformational stability of protease-sensitive and protease-resistant PrPSc.

Authors:  Laura Pirisinu; Michele Di Bari; Stefano Marcon; Gabriele Vaccari; Claudia D'Agostino; Paola Fazzi; Elena Esposito; Roberta Galeno; Jan Langeveld; Umberto Agrimi; Romolo Nonno
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

10.  Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States.

Authors:  Silvio Notari; Francisco J Moleres; Stephen B Hunter; Ermias D Belay; Lawrence B Schonberger; Ignazio Cali; Piero Parchi; Wun-Ju Shieh; Paul Brown; Sherif Zaki; Wen-Quan Zou; Pierluigi Gambetti
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.